SORBENT REMOVAL OF ANTI-CANCER DRUGS

被引：0

作者：

RAHMAN, A

WINCHESTER, JF

KESSLER, A

SLAVIK, M

SCHEIN, P

机构：

[1] GEORGE WASHINGTON UNIV,SCH MED,VINCENT T LOMBARDI CANC RES CTR,DIV MED ONCOL,WASHINGTON,DC 20007

[2] GEORGE WASHINGTON UNIV,SCH MED,DIV NEPHROL,WASHINGTON,DC 20007

来源：

PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH | 1978年 / 19卷 / MAR期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：233 / 233

页数：1

共 50 条

[1] Anti-cancer drugs
Bergmann-Leitner, ES
CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (09) : 1077 - 1078
[2] Anti-cancer drugs
Bergmann-Leitner, Elke
CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (11) : 1048 - 1048
[3] Anti-Cancer Drugs
Bergmann-Leitner, Elke
CURRENT PHARMACEUTICAL DESIGN, 2009, 15 (07) : 730 - 731
[4] Teratogens as anti-cancer drugs
Blagosklonny, MV
CELL CYCLE, 2005, 4 (11) : 1518 - 1521
[5] Development of Anti-cancer Drugs
Arrondeau, Jennifer
Gan, Hui K.
Razak, Albiruni R. A.
Paoletti, Xavier
Le Tourneau, Christophe
DISCOVERY MEDICINE, 2010, 10 (53) : 355 - 362
[6] TESTING ANTI-CANCER DRUGS
不详
LANCET, 1972, 1 (7755): : 827 - +
[7] HANDLING ANTI-CANCER DRUGS
不详
LANCET, 1983, 1 (8323): : 543 - 543
[8] Anti-cancer drugs for cardioprotection
Wu, Nan
Xie, Yizhen
Yang, Burton B.
CELL CYCLE, 2017, 16 (02) : 155 - 156
[9] TESTING ANTI-CANCER DRUGS
BERENBAUM, MC
SHEARD, CE
LANCET, 1972, 1 (7760): : 1116 - +
[10] Improved anti-cancer drugs
Barden, D
DALTON TRANSACTIONS, 2005, (11) : C42 - C42